Work

A phase 1 trial of the FACT inhibitor CBL0137 in pediatric patients with relapsed or refractory solid and CNS tumors: A report from the Children’s Oncology Group study PEPN2111.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.10051

Authors: David Simon Ziegler, Jason R. Fangusaro, Maria Tsoli, Orazio Vittorio, Tyler Shai-Hee, Charles Minard, Xiaowei Liu, Joel M. Reid, Nawal A. Yahya, Jennie Haunani Foster, Elizabeth Fox, Brenda Weigel

Institutions: Sydney Children's Hospital, Children's Healthcare of Atlanta, UNSW Sydney, Baylor College of Medicine, Children's Oncology Group, Mayo Clinic, St. Jude Children's Research Hospital, University of Minnesota

Language: English

Topic: Chromatin Remodeling and Cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410805588

Cites:

Cited by: 1

Related to: 10